The renal anemia market will expand over our 2016-2026 study period, fueled by increasing prevalence and a high unmet need for drugs that can effectively, safely, and conveniently control the disease. A series of hypoxia inducible factor prolyl hydroxylase (HIF PH) inhibitors are expected to launch over the study period, which will promote market growth. However, these novel therapies will have to demonstrate safety and efficacy benefits over current therapies in order to succeed. Among the HIF PH inhibitors, the most advanced agent is FibroGen/AstraZeneca/Astellas’ roxadustat, which is the subject of several long term Phase III trials. Although these new therapies are expected to demonstrate advantages over current therapies, they will face major challenges, including reimbursement hurdles and an increasingly stringent regulatory environment.
This report provides answers to the following questions:
Disease Landscape & Forecast Solution
This report provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research. Learn more about how you can quickly identify, analyze, and act on emerging challenges with timely and accurate insights DRG’s Insights Platform.